Sign in
Taking peoplePhase 3

Continued treatment with MHB018A for moderate-to-severe thyroid eye disease

Tests MHB018A injection in adults with moderate-to-severe thyroid eye disease.

Key facts

Who runs it
Minghui Pharmaceutical (Hangzhou) Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Status
Recruiting
Phase
Phase 3
People taking part
258 people, planned
Started
9 Jan 2026
Expected to end
31 Jan 2030
Type of study
Interventional
Treatments tested
  • MHB018A injection
Record updated
30 March 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Subjects voluntarily participating in the study and signing the informed consent form
  • Aged 18-75 years (inclusive), of any gender
  • Completed the 24-week double-blind treatment period in either the MHB018A-P-301 or MHB018A-P-302 study, and within 28 days after Week 24 visit of the previous study when enrolled in this OLE study (does not apply to subjects who meet the relapse criteria during the safety follow-up period)
  • Proptosis non-responder at Week 24 visit in the double-blind treatment period of either the MHB018A-P-301 or MHB018A-P-302 study (defined as a <2 mm reduction from baseline in the study eye, or a ≥2 mm reduction in the study eye accompanied by a ≥2 mm worsening from baseline in proptosis of the fellow eye), and/or who meet the retreatment criteria for relapse during the safety follow-up period
  • Does not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study
  • Diabetic subjects must have well-controlled stable disease
  • Sufficient bone marrow and organ function
  • Eligible subjects of childbearing potential (male and female) must agree to use reliable contraceptive methods; female subjects of childbearing potential must have a negative blood pregnancy test within 7 days before the first use of the study drug and must not be breastfeeding
  • Subject is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study; -

Who cannot take part

  • Received any treatment for TED, intravenous corticosteroids, immunosuppressive agents, investigational drug from the last visit of the MHB018A-P-301 or MHB018A-P-302 trial until participation in this study
  • Acute cardiovascular disease history or treatment within 6 months before the first dose from the last visit of the MHB018A-P-301 or MHB018A-P-302 trial until participation in this study
  • Identified pre-existing ophthalmic disease that would preclude study participation or complicate interpretation of the study results
  • Presence of poorly controlled hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; Renal artery stenosis
  • Tinnitus or other hearing impairment
  • Poor compliance or severe systemic disease history or other reasons that make the subject unsuitable for participation in this clinical study; -
  • Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision within the last 6 months of two lines of Snellen chart, new visual field defect or color defect secondary to optic nerve involvement
  • Corneal decompensation unresponsive to medical management
  • Free thyroxine (FT4) and free triiodothyronine (FT3) levels <50% above or below the normal reference range at screening
  • Pregnant or lactating women

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

The group in the trial

  • MHB018A InjectionTreatment being tested

    Subcutaneous injections of MHB018A injection, 450mg once every 4 weeks (q4w).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Multicenter, Open-Label Extension Study to Evaluate the Efficacy and Safety of MHB018A Injection in Subjects With Thyroid Eye Disease
Plain-language title
Continued treatment with MHB018A for moderate-to-severe thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
Fit questions
Built from NCT07262476, who can take part
Record updated
30 March 2026